This story has been updated to include information from a conference call to discuss Quidel's earnings.

NEW YORK (GenomeWeb) – Diagnostics manufacturer Quidel reported after the close of the market on Wednesday that its fourth quarter revenues rose approximately 1 percent year over year, due largely to higher sales of immunoassay, molecular, and specialty products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.